Fondazione Policlinico Universitario Agostino Gemelli
Welcome,         Profile    Billing    Logout  
 87 Trials 
889 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Costamagna, Guido
NCT04130659 / 2019-004062-17: Study to Evaluate the Performance and Safety of the MARIAL® in Association With PPI Versus PPI Alone

Recruiting
N/A
110
Europe
MARIAL® + PPI (generic Omeprazole), PPI alone (generic omeprazole), MARIAL® alone
Nekkar Lab Srl, Opera CRO, a TIGERMED Group Company
Gastroesophageal Reflux Disease (GERD)
12/24
01/25
NCT03421340: Non-Complex Biliary Stones DSC vs ERC

Completed
N/A
250
Europe, US, RoW
DSC, Direct Solitary Cholangioscopy, ERC, Endoscopic Retrograde Cholangiography
Boston Scientific Corporation
Biliary Stones
09/23
10/23
FARE, NCT05504434: Performance of a Single-use Gastroscope (aScope Gastro) for Esophagogastroduodenoscopy

Completed
N/A
60
Europe
Single-use gastroscope
Erasmus Medical Center, Maag Lever Darm Stichting, Ambu A/S
Gastroscopy, Esophagogastroduodenoscopy, Equipment Design, Equipment Contamination / Prevention & Control, Cross Infection / Prevention & Control, Disposable Equipment, Infection Control / Methods
12/23
12/23
AMGI REGISTRY, NCT04708288: A PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, POST MARKET OBSERVATIONAL STUDY TO EVALUATE THE SAFETY AND CLINICAL PERFORMANCE OF THE ARCHIMEDES BIODEGRADABLE BILIARY AND PANCREATIC STENT

Recruiting
N/A
198
Europe, RoW
ARCHIMEDES Biodegradable Biliary and Pancreatic Stent
QualiMed Innovative Medizinprodukte GmbH
Obstructed Biliary and Pancreatic Duct
12/23
12/23
NCT05248750: Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma

Recruiting
N/A
250
Europe
Catholic University of the Sacred Heart
Pancreas Cancer
07/24
07/26
Reck, Martin
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Recruiting
4
136
Europe
Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed
Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-Small Cell Lung Cancer Metastatic
10/25
10/26
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/29
02/32
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting
3
670
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung
03/26
03/28
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
SPACE, NCT04221529 / 2019-001707-21: Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Active, not recruiting
2
70
Europe
Atezolizumab
AIO-Studien-gGmbH, Hoffmann-La Roche
SCLC, Extensive Stage
04/24
04/25
NICITA, NCT04177953 / 2019-002466-13: Nivolumab with Chemotherapy in Pleural Mesothelioma After Surgery

Completed
2
92
Europe
Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb, Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg
Pleural Mesothelioma Malignant
01/25
01/25
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed
2
176
Europe, Canada, US, RoW
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608
GlaxoSmithKline, iTeos Belgium SA
Neoplasms
05/24
05/24
LCNEC-ALPINE, NCT05470595 / 2020-002683-31: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Active, not recruiting
2
67
Europe
Atezolizumab
Technische Universität Dresden, Roche Pharma AG
Large Cell Neuroendocrine Carcinoma of the Lung
01/28
01/29
NintNivo, NCT04046614: Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology

Completed
1/2
56
Europe
nintedanib-nivolumab combination therapy
AIO-Studien-gGmbH
Adenocarcinoma of the Lung
05/23
09/23
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

Active, not recruiting
N/A
420
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
NCT04600206: Existential Distress in Patients with Advanced Cancer and Their Caregivers

Completed
N/A
800
Europe
Self-report questionnaires
Universitätsklinikum Hamburg-Eppendorf
Neoplasms Malignant, Carcinoma, Palliative Care
12/24
12/24
MRD LUNG, NCT06111807: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics - Stage III NSCLC

Recruiting
N/A
248
Europe
ctDNA
University Medical Center Groningen, LungenClinic Grosshansdorf, Centre Hospitalier Universitaire de Nice
Lung Cancer Stage III
12/25
07/30
HANSE, NCT04913155: - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort

Recruiting
N/A
12100
Europe
Low-dose CT screening
Hannover Medical School, LungenClinic Grosshansdorf, University Hospital Schleswig-Holstein, German Center for Lung Research
Lung Cancer
06/26
01/28
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
Mingrone, Geltrude
FLAMES, NCT06374875: Fibrosis Lessens After Metabolic Surgery

Recruiting
4
120
Europe, Canada, US, RoW
Metabolic surgery, Bariatric surgery, Roux-en-Y Gastric Bypass (RYGB), Sleeve Gastrectomy (SG), Incretin-Based Therapy, Glucagon-like Peptide-1 Receptor Agonist
Ali Aminian
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
05/29
12/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting
2
72
Europe, US
Pasireotide Diaspartate, Pasireotide
RECORDATI GROUP
Post-Bariatric Hypoglycemia
04/25
04/26
CONNECT, NCT04653103: NASH in Subjects With Different Classes of Obesity

Active, not recruiting
N/A
500
Europe
Liver biopsy
Catholic University of the Sacred Heart
NASH - Nonalcoholic Steatohepatitis, NAFLD, Obesity, Obesity, Morbid
01/21
01/23
CROSS-CO19, NCT05736900: Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19

Completed
N/A
200
Europe
Blood sampling
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
02/21
06/21
CoV-miR, NCT05739513: A Specific miRNA Encoded by SARS-CoV-2 as a Diagnostic Tool to Predict Disease Severity in COVID-19 Patients

Completed
N/A
120
Europe
miRNA analysis in plasma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
07/21
07/21
NCT05755321: From Skin Fibroblasts to Neural Stem Cells to Investigate in Vitro the Impact of Diabetes on Adult Neurogenesis

Active, not recruiting
N/A
40
Europe
Skin biopsy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese, Diabetes Mellitus Type 2 in Nonobese, Obesity, Cognitive Dysfunction, Metabolism Disorder
04/23
05/23
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
FRIN, NCT05798702: Fibrosis Reduction in Non Alcoholic Steatohepatitis

Active, not recruiting
N/A
20
Europe
roux -en-y- gastric bypass, intensive life style modification
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NASH With Fibrosis, Weight Loss, Bariatric Surgery Candidate
09/25
09/26
Richeldi, Luca
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF
Active, not recruiting
2
48
Europe, RoW
RXC007, Placebo
Redx Pharma Plc, Simbec-Orion Group
IPF, Fibrosis
06/24
01/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
150
Europe, Canada, US, RoW
GSK3915393, Placebo
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
03/26
03/26
SATCoV, NCT05731583: Telemonitoraggio Domiciliare Della Saturazione Arteriosa di Ossigeno in Pazienti COVID-19

Recruiting
N/A
300
Europe
Home pulse oximetry monitoring
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
07/21
01/24
IRENE, NCT03339063: The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital, Azienda Ospedaliera San Gerardo di Monza, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Italy, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Unità Locale Socio Sanitaria n.9 Treviso, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli Studi di Ferrara, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Jacopo, Pistoia, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Policlinico Umberto I, Istituto Nazionale per le Malattie Infettive Spallanzani, Roma, Policlinico Universitario, Catania, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Cosenza, Azienda Ospedaliero Universitaria di Sassari
Nontuberculous Mycobacteria
12/22
12/22
ASSESS-CRC, NCT04078542: Prevalence and Main Features of Chronic Refractory Cough.

Not yet recruiting
N/A
400
Europe
Campus Bio-Medico University
Cough
12/22
12/22
USINCHILD, NCT03556488: Ultrasonographic Air Bronchogram in Pediatric CAP

Recruiting
N/A
30
Europe
US air bronchogram score
Catholic University of the Sacred Heart
Pneumonia, Pediatric Infectious Disorder
03/24
04/24
AIRVO-BX, NCT04102774: Effect of AIRVO Heated Humidification in Bronchiectasis

Active, not recruiting
N/A
130
Europe
Over-night treatment with myAIRVO2
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione Salvatore Maugeri, Università degli Studi di Ferrara, Azienda Ospedaliero, Universitaria Pisana, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale San Paolo, Universita degli Studi di Catania, Azienda Ospedaliera di Padova, University of Palermo, Azienda Ospedaliero-Universitaria di Parma, University of Foggia, Monaldi Hospital, Fondazione Don Carlo Gnocchi Onlus, Ospedale San Donato
Bronchiectasis Adult
01/25
01/25
RESPIRARE, NCT06645977: Patients With Interstitial Lung Disease

Recruiting
N/A
1200
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Interstitial Lung Disease
04/25
04/25
NCT05826613: Respiratory Registry for Lung Health: a Prospective, Observational Study on Adult Patients With Asthma or COPD

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Obstructive Pulmonary Disease, Asthma
05/24
05/24
PRIME-PPF, NCT06855329: PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Not yet recruiting
N/A
500
US
University of Massachusetts, Worcester, University of Michigan, University of Virginia, Johannes Gutenberg University Mainz, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
12/29
12/29
Sica, Simona
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT05319587 / 2020-005493-10: Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML)

Active, not recruiting
1/2
63
Europe
Liposomal Annamycin, Cytarabine
Moleculin Biotech, Inc., Moleculin Biotech, Inc.
Leukemia, Myeloid, Acute
08/23
04/25
NCT04709458: Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Not yet recruiting
1
10
Europe, RoW
TBX-2400
Taiga Biotechnologies, Inc.
Myelofibrosis, Acute Myelogenous Leukemia
08/24
10/24
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
Europe, US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML with Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
ATREMA, NCT04355130: Autologous Tansfusion REquirements in Bone MArrow Harvest: The Study

Completed
N/A
7
Europe
Iron, vitamin B12 and acid folic supplementation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bone Marrow Donors
12/22
12/22
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

Recruiting
N/A
32
Europe
bone marrow and/or peripheral blood samples withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All
05/24
05/24
Gasbarrini, Antonio
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
PACER, NCT01801904 / 2010-024490-39: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer

Active, not recruiting
2
52
Europe
Panitumumab
National Cancer Institute, Naples, Azienda Ospedaliera G. Rummo
Metastatic Colorectal Cancer
12/24
12/24
NCT05016024: Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.

Completed
N/A
71
Europe
Colilen IBS, Placebo
Aboca Spa Societa' Agricola, IQVIA RDS, IQVIA Solutions
Irritable Bowel Syndrome
02/23
02/23
HDV Describe, NCT05723068: Burden of Hepatitis D Virus (HDV) Infection in Italy

Completed
N/A
515
Europe
University of Turin, Italy, Gilead Sciences
Chronic Hepatitis D
06/24
12/24
CROSSWORD, NCT05756582: Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students

Recruiting
N/A
2040
Europe
Prevalence of Latent Tuberculosis Infection
Eleonora Nucera
Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis Infection, Latent Tuberculosis, Health Care Associated Infection
06/26
12/26
Cauda, Roberto RC
EDOLAS, NCT04979468: Early DOlutegravir/LAmivudine Switching After Virological Suppression ( Study)

Recruiting
3
440
Europe
DOVATO, dolutegravir/lamivudine
Societa' Italiana Di Malattie Infettive E Tropicali
HIV-1-infection
04/23
04/24
MANTICO 2, NCT05321394: Non-inferiority Trial on Treatments in Early COVID-19

Completed
3
536
Europe
Sotrovimab, Tixagevimab Cilgavimab, Nirmatrelvir Ritonavir
Azienda Ospedaliera Universitaria Integrata Verona, Agenzia Italiana del Farmaco, Azienda Sanitaria-Universitaria Integrata di Udine
COVID-19
10/23
10/23
Laurenti, Luca
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
VIS, NCT05478512 / 2022-002579-12: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

Recruiting
2
78
Europe
VenObi+Ven or VenObi+VenZan
Gruppo Italiano Malattie EMatologiche dell'Adulto, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus
High Risk CLL, Chronic Lymphocytic Leukemia
05/26
07/27
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting
N/A
321
Europe
Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
01/23
10/25
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting
N/A
190
Europe
acalabrutinib, Calquence
AstraZeneca, Yghea
Chronic Lymphocytic Leukemia
02/30
02/30
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26
Conti, Giorgio
NCT05751174: Determination of Nerve Growth Factor (NGF) Expression in Pediatric Patients With Severe Burns: a Pilot Study

Completed
N/A
12
Europe
pediatric patients affected by severe burns
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Burns
05/22
08/22
PULSAR, NCT06020404: Prone Position in infantS/Children With Acute Respiratory Distress Syndrome

Recruiting
N/A
15
Europe
supine position, prone position
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prone Position, Acute Respiratory Distress Syndrome
09/24
09/25
Irving, Peter
STATIC, NCT03261206 / 2018-001382-17: Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Active, not recruiting
4
334
Europe, Canada, RoW
5-ASA Withdrawal
Alimentiv Inc., Academic Medical Organization of Southwestern Ontario
Crohn Disease, Remission
06/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
TRIBUTE, NCT03185000: Treg Immunotherapy in Crohn's Disease

Recruiting
1
4
Europe
TR004 (Treg immunotherapy), Autologous regulatory T cells (Tregs) expanded in vitro
King's College London, Guy's and St Thomas' NHS Foundation Trust, Medical Research Council, St. George's Hospital, London, Miltenyi biotech
Crohn Disease
03/24
06/25
INSIGHT, NCT05713409: Prediction and Close Monitoring of Postoperative Recurrence by Intestinal Ultrasound After Ileocecal Resection in Crohn's Disease Patients

Recruiting
N/A
120
Europe
Intestinal ultrasound
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Crohn Disease
12/24
05/25
Trani, Carlo
NCT04091048: Optimize PRO Study

Completed
N/A
1127
Europe, Canada, US, RoW
Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Medtronic Cardiovascular
Symptomatic Aortic Stenosis
12/23
11/24
VISTA, NCT06008080: Post-Market Clinical Follow Up Study With Navitor Valve

Recruiting
N/A
1000
Europe, Japan
Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System
Abbott Medical Devices
Aortic Stenosis
01/26
12/30
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Contzen, Christel
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
15500
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
Mercuri, Eugenio
RESPOND, NCT04488133 / 2020-003492-18: A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Active, not recruiting
4
46
Europe, US, RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Muscular Atrophy, Spinal
10/25
10/25
ENVISION, NCT05881408 / 2020-002372-13: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting
3
148
Europe, Japan, US, RoW
delandistrogene moxeparvovec, SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS, placebo
Sarepta Therapeutics, Inc., Hoffmann-La Roche
Duchenne Muscular Dystrophy
05/27
06/28
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Recruiting
3
45
Europe, Japan, US
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
ULYSSES, NCT05933057: Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Recruiting
3
138
Europe, Canada
Givinostat, ITF2357, Placebo
Italfarmaco, Fortrea
Duchenne Muscular Dystrophy
02/28
02/28
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Terminated
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
02/25
SYNAPSE-SMA, NCT05794139 / 2022-002301-24: Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

Recruiting
2
54
Europe, Canada, US
NMD670, Placebo
NMD Pharma A/S, NMD Pharma A/S
Spinal Muscular Atrophy
01/26
01/26
NCT06769633: Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

Not yet recruiting
2
18
Europe
Givinostat Hydrochloride, Cohort 1, Givinostat Hydrochloride - Cohort 2, Cohort 2
Italfarmaco, Fortrea
Duchenne Muscular Dystrophy
12/29
12/29
CircSMA, NCT05760209: SMN Circular RNAs as Potential New Targets and Biomarkers for SMA

Recruiting
N/A
30
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Spinal Muscular Atrophy
07/24
07/24
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Costamagna, Guido
NCT04130659 / 2019-004062-17: Study to Evaluate the Performance and Safety of the MARIAL® in Association With PPI Versus PPI Alone

Recruiting
N/A
110
Europe
MARIAL® + PPI (generic Omeprazole), PPI alone (generic omeprazole), MARIAL® alone
Nekkar Lab Srl, Opera CRO, a TIGERMED Group Company
Gastroesophageal Reflux Disease (GERD)
12/24
01/25
NCT03421340: Non-Complex Biliary Stones DSC vs ERC

Completed
N/A
250
Europe, US, RoW
DSC, Direct Solitary Cholangioscopy, ERC, Endoscopic Retrograde Cholangiography
Boston Scientific Corporation
Biliary Stones
09/23
10/23
FARE, NCT05504434: Performance of a Single-use Gastroscope (aScope Gastro) for Esophagogastroduodenoscopy

Completed
N/A
60
Europe
Single-use gastroscope
Erasmus Medical Center, Maag Lever Darm Stichting, Ambu A/S
Gastroscopy, Esophagogastroduodenoscopy, Equipment Design, Equipment Contamination / Prevention & Control, Cross Infection / Prevention & Control, Disposable Equipment, Infection Control / Methods
12/23
12/23
AMGI REGISTRY, NCT04708288: A PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, POST MARKET OBSERVATIONAL STUDY TO EVALUATE THE SAFETY AND CLINICAL PERFORMANCE OF THE ARCHIMEDES BIODEGRADABLE BILIARY AND PANCREATIC STENT

Recruiting
N/A
198
Europe, RoW
ARCHIMEDES Biodegradable Biliary and Pancreatic Stent
QualiMed Innovative Medizinprodukte GmbH
Obstructed Biliary and Pancreatic Duct
12/23
12/23
NCT05248750: Genetic, Microenvironmental, and Immunological Factors in Unresectable Pancreatic Ductal Adenocarcinoma

Recruiting
N/A
250
Europe
Catholic University of the Sacred Heart
Pancreas Cancer
07/24
07/26
Reck, Martin
ANTELOPE, NCT05689671: Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma

Recruiting
4
136
Europe
Atezolizumab, Tecentriq, Nab paclitaxel, Abraxane, Carboplatin, Pembrolizumab, Keytruda, Cisplatin, Pemetrexed
Nikolaj Frost MD, Roche Pharma AG, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Non-Small Cell Lung Cancer Metastatic
10/25
10/26
SUNRAY-02, NCT06890598: Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Recruiting
3
700
Europe, Japan, US, RoW
Olomorasib, LY3537982, Pembrolizumab, Durvalumab, Placebo
Eli Lilly and Company, AstraZeneca
Carcinoma, Non-Small-Cell Lung
05/29
02/32
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Recruiting
3
1016
Europe, Canada, Japan, US, RoW
LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
10/26
10/29
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

Recruiting
3
670
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen, a wholly owned subsidiary of Pfizer
Carcinoma, Non-Small-Cell Lung
03/26
03/28
LIBRETTO-432, NCT04819100 / 2020-005191-35: A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting
3
152
Europe, Canada, Japan, US, RoW
Selpercatinib, LY3527723, LOXO-292, Placebo
Eli Lilly and Company, Loxo Oncology, Inc.
Carcinoma, Non-Small-Cell Lung
05/26
05/28
SPACE, NCT04221529 / 2019-001707-21: Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

Active, not recruiting
2
70
Europe
Atezolizumab
AIO-Studien-gGmbH, Hoffmann-La Roche
SCLC, Extensive Stage
04/24
04/25
NICITA, NCT04177953 / 2019-002466-13: Nivolumab with Chemotherapy in Pleural Mesothelioma After Surgery

Completed
2
92
Europe
Carboplatin AUC 5, Cisplatin 75 mg/m2, Pemetrexed 500 mg/m2, Nivolumab Injection, Opdivo
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Bristol-Myers Squibb, Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg
Pleural Mesothelioma Malignant
01/25
01/25
GALAXIES LUNG-201, NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
340
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, GSK4057190, Belrestotug, EOS884448, GSK4428859A, Nelistotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
10/25
10/28
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Completed
2
176
Europe, Canada, US, RoW
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608
GlaxoSmithKline, iTeos Belgium SA
Neoplasms
05/24
05/24
LCNEC-ALPINE, NCT05470595 / 2020-002683-31: A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung

Active, not recruiting
2
67
Europe
Atezolizumab
Technische Universität Dresden, Roche Pharma AG
Large Cell Neuroendocrine Carcinoma of the Lung
01/28
01/29
NintNivo, NCT04046614: Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology

Completed
1/2
56
Europe
nintedanib-nivolumab combination therapy
AIO-Studien-gGmbH
Adenocarcinoma of the Lung
05/23
09/23
ALKOVE-1, NCT05384626 / 2022-000122-21: A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation

Recruiting
1/2
470
Europe, Canada, Japan, US, RoW
NVL-655
Nuvalent Inc., Nuvalent, Inc.
Locally Advanced Solid Tumor, Metastatic Solid Tumor
02/26
03/26
NCT01817192: Adjuvant Chemotherapy in Patients With Intermediate or High Risk Stage I or Stage IIA Non-squamous Non-Small Cell Lung Cancer: AIM-HIGH (Adjuvant Intervention in Molecular High Risk Patients)

Active, not recruiting
N/A
420
Europe, US
Adjuvant Chemotherapy, Radiographic surveillance, 14-Gene Prognostic Assay
Razor Genomics, Encore Clinical
Non-Small Cell Lung Cancer
05/27
05/27
NCT04600206: Existential Distress in Patients with Advanced Cancer and Their Caregivers

Completed
N/A
800
Europe
Self-report questionnaires
Universitätsklinikum Hamburg-Eppendorf
Neoplasms Malignant, Carcinoma, Palliative Care
12/24
12/24
MRD LUNG, NCT06111807: Clinical Validation and Benchmarking of Top Performing CtDNA Diagnostics - Stage III NSCLC

Recruiting
N/A
248
Europe
ctDNA
University Medical Center Groningen, LungenClinic Grosshansdorf, Centre Hospitalier Universitaire de Nice
Lung Cancer Stage III
12/25
07/30
HANSE, NCT04913155: - Holistic Implementation Study Assessing a Northern German Interdisciplinary Lung Cancer Screening Effort

Recruiting
N/A
12100
Europe
Low-dose CT screening
Hannover Medical School, LungenClinic Grosshansdorf, University Hospital Schleswig-Holstein, German Center for Lung Research
Lung Cancer
06/26
01/28
NCT05376891: Met Non Small Cell Cancer Registry (MOMENT)

Recruiting
N/A
700
Europe, Canada, US, RoW
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany
Cancer
03/27
03/27
Mingrone, Geltrude
FLAMES, NCT06374875: Fibrosis Lessens After Metabolic Surgery

Recruiting
4
120
Europe, Canada, US, RoW
Metabolic surgery, Bariatric surgery, Roux-en-Y Gastric Bypass (RYGB), Sleeve Gastrectomy (SG), Incretin-Based Therapy, Glucagon-like Peptide-1 Receptor Agonist
Ali Aminian
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH), Liver Fibrosis, Obesity
05/29
12/29
NCT06383390: The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Recruiting
3
10000
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
02/29
02/29
PASIPHY, NCT05928390: Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia

Recruiting
2
72
Europe, US
Pasireotide Diaspartate, Pasireotide
RECORDATI GROUP
Post-Bariatric Hypoglycemia
04/25
04/26
CONNECT, NCT04653103: NASH in Subjects With Different Classes of Obesity

Active, not recruiting
N/A
500
Europe
Liver biopsy
Catholic University of the Sacred Heart
NASH - Nonalcoholic Steatohepatitis, NAFLD, Obesity, Obesity, Morbid
01/21
01/23
CROSS-CO19, NCT05736900: Counter-Regulatory Hormonal and Stress Systems in Patients With COVID-19

Completed
N/A
200
Europe
Blood sampling
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
02/21
06/21
CoV-miR, NCT05739513: A Specific miRNA Encoded by SARS-CoV-2 as a Diagnostic Tool to Predict Disease Severity in COVID-19 Patients

Completed
N/A
120
Europe
miRNA analysis in plasma
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
07/21
07/21
NCT05755321: From Skin Fibroblasts to Neural Stem Cells to Investigate in Vitro the Impact of Diabetes on Adult Neurogenesis

Active, not recruiting
N/A
40
Europe
Skin biopsy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Diabetes Mellitus, Type 2, Diabetes Mellitus Type 2 in Obese, Diabetes Mellitus Type 2 in Nonobese, Obesity, Cognitive Dysfunction, Metabolism Disorder
04/23
05/23
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Suspended
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
FRIN, NCT05798702: Fibrosis Reduction in Non Alcoholic Steatohepatitis

Active, not recruiting
N/A
20
Europe
roux -en-y- gastric bypass, intensive life style modification
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
NASH With Fibrosis, Weight Loss, Bariatric Surgery Candidate
09/25
09/26
Richeldi, Luca
FGCL-3019-095, NCT04419558 / 2020-000697-22: Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Apr 2024 - Sep 2024: Topline data from ZEPHYRUS-2 trial for IPF
Terminated
3
372
Europe, US, RoW
Pamrevlumab, FG-3019, Placebo
FibroGen
Idiopathic Pulmonary Fibrosis
09/23
09/23
TETON-2, NCT05255991 / 2021-005881-17: Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

Active, not recruiting
3
597
Europe, RoW
Placebo, Inhaled Treprostinil, Tyvaso, Treprostinil Ultrasonic Nebulizer
United Therapeutics
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
07/25
07/25
RXC007 0002, NCT05570058 / 2022-000498-15: Assess the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of RXC007 in Idiopathic Pulmonary Fibrosis

Hourglass Jan 2024 - Mar 2024 : Q1'24 - Topline data from trial for IPF
Active, not recruiting
2
48
Europe, RoW
RXC007, Placebo
Redx Pharma Plc, Simbec-Orion Group
IPF, Fibrosis
06/24
01/25
NCT06317285: A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
2
150
Europe, Canada, US, RoW
GSK3915393, Placebo
GlaxoSmithKline
Idiopathic Pulmonary Fibrosis
03/26
03/26
SATCoV, NCT05731583: Telemonitoraggio Domiciliare Della Saturazione Arteriosa di Ossigeno in Pazienti COVID-19

Recruiting
N/A
300
Europe
Home pulse oximetry monitoring
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
COVID-19
07/21
01/24
IRENE, NCT03339063: The Italian REgistry of Pulmonary Non-tuberculous mycobactEria

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Niguarda Hospital, Azienda Ospedaliera San Gerardo di Monza, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Turin, Italy, A.O.U. Città della Salute e della Scienza - Molinette Hospital, Azienda Unità Locale Socio Sanitaria n.9 Treviso, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Università degli Studi di Ferrara, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Azienda Ospedaliero, Universitaria Pisana, Azienda Ospedaliero-Universitaria Careggi, Ospedale San Jacopo, Pistoia, Italy, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Azienda Policlinico Umberto I, Istituto Nazionale per le Malattie Infettive Spallanzani, Roma, Policlinico Universitario, Catania, Azienda Ospedaliera Universitaria Policlinico "G. Martino", Azienda Ospedaliera Cosenza, Azienda Ospedaliero Universitaria di Sassari
Nontuberculous Mycobacteria
12/22
12/22
ASSESS-CRC, NCT04078542: Prevalence and Main Features of Chronic Refractory Cough.

Not yet recruiting
N/A
400
Europe
Campus Bio-Medico University
Cough
12/22
12/22
USINCHILD, NCT03556488: Ultrasonographic Air Bronchogram in Pediatric CAP

Recruiting
N/A
30
Europe
US air bronchogram score
Catholic University of the Sacred Heart
Pneumonia, Pediatric Infectious Disorder
03/24
04/24
AIRVO-BX, NCT04102774: Effect of AIRVO Heated Humidification in Bronchiectasis

Active, not recruiting
N/A
130
Europe
Over-night treatment with myAIRVO2
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, ASST Fatebenefratelli Sacco, Fondazione IRCCS Policlinico San Matteo di Pavia, Ospedale Maggiore Di Trieste, Azienda Ospedaliero-Universitaria di Modena, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Fondazione Salvatore Maugeri, Università degli Studi di Ferrara, Azienda Ospedaliero, Universitaria Pisana, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Ospedale San Paolo, Universita degli Studi di Catania, Azienda Ospedaliera di Padova, University of Palermo, Azienda Ospedaliero-Universitaria di Parma, University of Foggia, Monaldi Hospital, Fondazione Don Carlo Gnocchi Onlus, Ospedale San Donato
Bronchiectasis Adult
01/25
01/25
RESPIRARE, NCT06645977: Patients With Interstitial Lung Disease

Recruiting
N/A
1200
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Interstitial Lung Disease
04/25
04/25
NCT05826613: Respiratory Registry for Lung Health: a Prospective, Observational Study on Adult Patients With Asthma or COPD

Recruiting
N/A
500
Europe
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Chronic Obstructive Pulmonary Disease, Asthma
05/24
05/24
PRIME-PPF, NCT06855329: PRospective phenotypIng and Multi-omic Endotyping of Progressive Pulmonary Fibrosis

Not yet recruiting
N/A
500
US
University of Massachusetts, Worcester, University of Michigan, University of Virginia, Johannes Gutenberg University Mainz, Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Progressive Pulmonary Fibrosis, Interstitial Lung Disease
12/29
12/29
Sica, Simona
ALLELE, NCT03394365 / 2017-002949-30: Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Checkmark Data from ALLELE trial for post-transplant lymphoproliferative disease
Dec 2021 - Dec 2021: Data from ALLELE trial for post-transplant lymphoproliferative disease
Recruiting
3
66
Europe, Canada, US, RoW
tabelecleucel, tab-cel®, ATA129, EBV-CTL
Atara Biotherapeutics
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
08/25
06/27
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
NCT05319587 / 2020-005493-10: Study of Liposomal Annamycin in Combination with Cytarabine for the Treatment of Subjects with Acute Myeloid Leukemia (AML)

Active, not recruiting
1/2
63
Europe
Liposomal Annamycin, Cytarabine
Moleculin Biotech, Inc., Moleculin Biotech, Inc.
Leukemia, Myeloid, Acute
08/23
04/25
NCT04709458: Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis

Not yet recruiting
1
10
Europe, RoW
TBX-2400
Taiga Biotechnologies, Inc.
Myelofibrosis, Acute Myelogenous Leukemia
08/24
10/24
NCT06001788: Safety and Tolerability of Ziftomenib Combinations in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Recruiting
1
171
Europe, US
Ziftomenib, KO-539, Fludarabine, Idarubicin, Cytarabine, Gilteritinib, Xospata, Granulocyte colony-stimulating factor
Kura Oncology, Inc.
AML, AML with Mutated NPM1, Hematologic Malignancy, KMT2Ar, NPM1 Mutation, MLL Rearrangement, Leukemia, Acute Myeloid Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Acute Leukemia, Neoplasms by Histologic Type
08/26
08/27
1621-QLG-LG, NCT03755856: Long-term Outcomes for Acute Myeloid Leukemia Patients

Recruiting
N/A
343
Europe, RoW
Questionnaire
Gruppo Italiano Malattie EMatologiche dell'Adulto, European Organisation for Research and Treatment of Cancer - EORTC
Acute Myeloid Leukemia
06/21
12/22
CML1012, NCT01752062: Observational Study of Conception/Pregnancy in Adult Patients With CML Treated With Tyrosine Kinase Inhibitors

Recruiting
N/A
148
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Myeloid Leukemia, Pregnancy
12/22
12/22
ATREMA, NCT04355130: Autologous Tansfusion REquirements in Bone MArrow Harvest: The Study

Completed
N/A
7
Europe
Iron, vitamin B12 and acid folic supplementation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bone Marrow Donors
12/22
12/22
NCT04460950: Observational Study for the Evaluation of Incidence of Familial AML/MDSs in Patients With Myeloid Neoplasms

Recruiting
N/A
237
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia, Familial Acute Myeloid Leukemia, Myelodysplastic Syndromes
03/25
03/25
NCT04582487: Advancing Chemical and Genomic Strategies for Relapsed/Refractory T-ALL and ETP-ALL

Recruiting
N/A
32
Europe
bone marrow and/or peripheral blood samples withdrawal
Gruppo Italiano Malattie EMatologiche dell'Adulto
T Acute Lymphoblastic Leukemia, Early T Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Etp All
05/24
05/24
Gasbarrini, Antonio
VECTORS, NCT06257706: - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

Recruiting
4
304
Europe, Canada, US, RoW
Vedolizumab
Alimentiv Inc., Takeda
Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
01/27
09/28
VERDICT, NCT04259138 / 2019-002485-12: Determination of the Optimal Treatment Target in Ulcerative Colitis

Active, not recruiting
4
672
Europe, Canada, US, RoW
Treatment Algorithm A, vedolizumab, Treatment Algorithm B, Treatment Algorithm C
Alimentiv Inc., Takeda Development Center Americas, Inc.
Colitis, Ulcerative
03/26
03/26
ABX464-106, NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting
3
612
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
03/25
04/25
LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Active, not recruiting
3
160
Europe, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis, Ulcerative Colitis Chronic
08/24
09/25

Recruiting
3
1050
Europe, Canada, Japan, US, RoW
ABX464, Obefazimod, Placebo
Abivax S.A.
Ulcerative Colitis
01/26
01/30
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting
2
268
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Crohn's Disease
09/26
07/27
NCT06254950: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting
2
207
Europe, Canada, Japan, US, RoW
TAK-279, Zasocitinib, Placebo
Takeda
Ulcerative Colitis
09/26
08/27
ENHANCE-CD, NCT06456593: Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting
2
212
Europe, US, RoW
Obefazimod, Placebo
Abivax S.A.
Moderately to Severely Active Crohn Disease
12/26
04/28
PACER, NCT01801904 / 2010-024490-39: A Phase 2 Study of Panitumumab in Patients With Cetuximab-refractory Metastatic Colorectal Cancer

Active, not recruiting
2
52
Europe
Panitumumab
National Cancer Institute, Naples, Azienda Ospedaliera G. Rummo
Metastatic Colorectal Cancer
12/24
12/24
NCT05016024: Administration of a Molecular Complex of Resins, Polysaccharides and Polyphenols in Irritable Bowel Syndrome.

Completed
N/A
71
Europe
Colilen IBS, Placebo
Aboca Spa Societa' Agricola, IQVIA RDS, IQVIA Solutions
Irritable Bowel Syndrome
02/23
02/23
HDV Describe, NCT05723068: Burden of Hepatitis D Virus (HDV) Infection in Italy

Completed
N/A
515
Europe
University of Turin, Italy, Gilead Sciences
Chronic Hepatitis D
06/24
12/24
CROSSWORD, NCT05756582: Prevalence of Latent Tuberculosis Infection in Health-care Workers and Students

Recruiting
N/A
2040
Europe
Prevalence of Latent Tuberculosis Infection
Eleonora Nucera
Tuberculosis, Tuberculosis, Pulmonary, Tuberculosis Infection, Latent Tuberculosis, Health Care Associated Infection
06/26
12/26
Cauda, Roberto RC
EDOLAS, NCT04979468: Early DOlutegravir/LAmivudine Switching After Virological Suppression ( Study)

Recruiting
3
440
Europe
DOVATO, dolutegravir/lamivudine
Societa' Italiana Di Malattie Infettive E Tropicali
HIV-1-infection
04/23
04/24
MANTICO 2, NCT05321394: Non-inferiority Trial on Treatments in Early COVID-19

Completed
3
536
Europe
Sotrovimab, Tixagevimab Cilgavimab, Nirmatrelvir Ritonavir
Azienda Ospedaliera Universitaria Integrata Verona, Agenzia Italiana del Farmaco, Azienda Sanitaria-Universitaria Integrata di Udine
COVID-19
10/23
10/23
Laurenti, Luca
BRUIN CLL-321, NCT04666038: Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
238
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN CLL-313, NCT05023980: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/25
08/26
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Active, not recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
CLL17, NCT04608318 / 2019-003854-99: Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)

Active, not recruiting
3
897
Europe, RoW
Ibrutinib, Imbruvica, Venetoclax, ABT-199, Venclyxto, Obinutuzumab, GA101, Gazyvaro
German CLL Study Group, Stichting Hemato-Oncologie voor Volwassenen Nederland (HOVON), Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research (SAKK), Cancer Trials Ireland, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), Grupo Español de Leucemia Linfocítica Crónica (GELLC), The Israeli CLL Study Group (ICLLSG), Janssen Pharmaceutica N.V., Belgium, AbbVie, Hoffmann-La Roche
Chronic Lymphoid Leukemia
09/27
09/27
CLL1818, NCT03804372 / 2019-000159-14: The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

Terminated
2
5
Europe
Rituximab, Chemotherapy, Tenofovir alafenamide
Gruppo Italiano Malattie EMatologiche dell'Adulto
Large-B-cell Diffuse Lymphoma, Chronic Lymphoid Leukemia
05/24
05/24
NCT06588478: A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Recruiting
2
249
Europe, Canada, US, RoW
Pirtobrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
06/28
12/28
VIS, NCT05478512 / 2022-002579-12: Front-line VenObi Combination Followed by Ven or VenZan Combination in Patients With Residual Disease: a MRD Tailored Treatment for Young Patients With High-risk CLL

Recruiting
2
78
Europe
VenObi+Ven or VenObi+VenZan
Gruppo Italiano Malattie EMatologiche dell'Adulto, BeiGene, Roche, Fondazione GIMEMA Franco Mandelli Onlus
High Risk CLL, Chronic Lymphocytic Leukemia
05/26
07/27
MOLTO, NCT04082897 / 2018-005028-40: ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmation

Active, not recruiting
2
28
Europe
Obinutuzumab 25 MG/ML [Gazyva], Atezolizumab 60 MG/ML [Tecentriq], Venetoclax Oral Tablet
Niguarda Hospital
CLL Transformation
09/26
12/26
GIMEMA, NCT04282811: Observational Study Relapsed or Refractory Chronic Lymphocytic Leukemia Venetoclax-based Regimens Outside Clinical Trials in Italy

Recruiting
N/A
321
Europe
Venetoclax
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Relapse Leukemia, Refractory Leukemia
01/23
10/25
ARISE, NCT06205498: Acalabrutinib Real World Italian obSErvational Study -

Recruiting
N/A
190
Europe
acalabrutinib, Calquence
AstraZeneca, Yghea
Chronic Lymphocytic Leukemia
02/30
02/30
GIMEMA, NCT04867915: Study on the Diagnosis and Management of CLL in Italy by

Recruiting
N/A
12500
Europe
Gruppo Italiano Malattie EMatologiche dell'Adulto
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, MBL-CLL - Monoclonal B-Cell Lymphocytosis Chronic Lymphocytic Leukaemia-Type
10/26
10/26
Conti, Giorgio
NCT05751174: Determination of Nerve Growth Factor (NGF) Expression in Pediatric Patients With Severe Burns: a Pilot Study

Completed
N/A
12
Europe
pediatric patients affected by severe burns
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Burns
05/22
08/22
PULSAR, NCT06020404: Prone Position in infantS/Children With Acute Respiratory Distress Syndrome

Recruiting
N/A
15
Europe
supine position, prone position
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Prone Position, Acute Respiratory Distress Syndrome
09/24
09/25
Irving, Peter
STATIC, NCT03261206 / 2018-001382-17: Stopping Aminosalicylate Therapy in Inactive Crohn's Disease

Active, not recruiting
4
334
Europe, Canada, RoW
5-ASA Withdrawal
Alimentiv Inc., Academic Medical Organization of Southwestern Ontario
Crohn Disease, Remission
06/26
06/26
LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Hourglass Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis
Recruiting
3
1063
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Ulcerative Colitis
07/26
12/27
TRIBUTE, NCT03185000: Treg Immunotherapy in Crohn's Disease

Recruiting
1
4
Europe
TR004 (Treg immunotherapy), Autologous regulatory T cells (Tregs) expanded in vitro
King's College London, Guy's and St Thomas' NHS Foundation Trust, Medical Research Council, St. George's Hospital, London, Miltenyi biotech
Crohn Disease
03/24
06/25
INSIGHT, NCT05713409: Prediction and Close Monitoring of Postoperative Recurrence by Intestinal Ultrasound After Ileocecal Resection in Crohn's Disease Patients

Recruiting
N/A
120
Europe
Intestinal ultrasound
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Crohn Disease
12/24
05/25
Trani, Carlo
NCT04091048: Optimize PRO Study

Completed
N/A
1127
Europe, Canada, US, RoW
Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Medtronic Cardiovascular
Symptomatic Aortic Stenosis
12/23
11/24
VISTA, NCT06008080: Post-Market Clinical Follow Up Study With Navitor Valve

Recruiting
N/A
1000
Europe, Japan
Navitor Transcatheter Aortic Valve, FlexNav Delivery System, Navitor Loading System
Abbott Medical Devices
Aortic Stenosis
01/26
12/30
PROTECT IV, NCT04763200: Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

Recruiting
N/A
1252
Europe, Canada, US
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Abiomed Inc.
Left Ventricular Dysfunction, Coronary Artery Disease
03/26
10/27
Contzen, Christel
RSV OA=ADJ=012, NCT06534892: An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

Recruiting
3
15500
Europe, Canada, Japan, US, RoW
RSVPreF3 OA vaccine
GlaxoSmithKline
Respiratory Syncytial Virus Infections
09/26
09/26
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Active, not recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
COMMIT-CD, NCT06937099: Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Not yet recruiting
3
290
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Crohn's Disease, Obesity or Overweight
05/28
05/28
COMMIT-UC, NCT06937086: Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Not yet recruiting
3
350
Europe, Canada, US, RoW
Mirikizumab, LY3074828, Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Ulcerative Colitis, Obesity or Overweight
04/28
04/28
Mercuri, Eugenio
RESPOND, NCT04488133 / 2020-003492-18: A Study to Learn About the Effect of Nusinersen (BIIB058) Given as Injections to Children With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Onasemnogene Abeparvovec

Active, not recruiting
4
46
Europe, US, RoW
Nusinersen, ISIS 396443, BIIB058, Spinraza
Biogen
Muscular Atrophy, Spinal
10/25
10/25
ENVISION, NCT05881408 / 2020-002372-13: A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)

Recruiting
3
148
Europe, Japan, US, RoW
delandistrogene moxeparvovec, SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS, placebo
Sarepta Therapeutics, Inc., Hoffmann-La Roche
Duchenne Muscular Dystrophy
05/27
06/28
ASCEND, NCT05067790 / 2021-001294-23: A Study to Learn About the Effect of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Were Previously Treated With Risdiplam

Recruiting
3
45
Europe, Japan, US
Nusinersen, BIIB058, Spinraza
Biogen
Spinal Muscular Atrophy
06/27
06/27
ULYSSES, NCT05933057: Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular Dystrophy

Recruiting
3
138
Europe, Canada
Givinostat, ITF2357, Placebo
Italfarmaco, Fortrea
Duchenne Muscular Dystrophy
02/28
02/28
MOMENTUM, NCT04004065 / 2019-000601-77: Two-Part Study for Dose Determination of Vesleteplirsen (SRP-5051) (Part A), Then Dose Expansion (Part B) in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

Checkmark From MOMENTUM trial for DMD
May 2021 - May 2021: From MOMENTUM trial for DMD
Checkmark Interim data from the MOMENTUM study
Dec 2020 - Dec 2020: Interim data from the MOMENTUM study
Checkmark Data from MOMENTUM trial for Duchenne muscular dystrophy
More
Terminated
2
62
Europe, Canada, US
Vesleteplirsen, SRP-5051
Sarepta Therapeutics, Inc.
Duchenne Muscular Dystrophy
10/23
02/25
SYNAPSE-SMA, NCT05794139 / 2022-002301-24: Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

Recruiting
2
54
Europe, Canada, US
NMD670, Placebo
NMD Pharma A/S, NMD Pharma A/S
Spinal Muscular Atrophy
01/26
01/26
NCT06769633: Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old

Not yet recruiting
2
18
Europe
Givinostat Hydrochloride, Cohort 1, Givinostat Hydrochloride - Cohort 2, Cohort 2
Italfarmaco, Fortrea
Duchenne Muscular Dystrophy
12/29
12/29
CircSMA, NCT05760209: SMN Circular RNAs as Potential New Targets and Biomarkers for SMA

Recruiting
N/A
30
Europe
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Spinal Muscular Atrophy
07/24
07/24
 

Download Options